Impact of erythropoietin on allogenic blood exposure in orthopedic surgery.
Joint reconstruction surgery is associated with significant blood loss, and patients often require perioperative transfusions. Recombinant human erythropoietin (epoetin) can be used in anemic patients scheduled for elective, noncardiac, nonvascular surgery to reduce the need for transfusions. In the study reported here, patients with a preoperative hemoglobin level of 10 to 13 g/dL were treated with epoetin. Our analysis showed that transfusions were given to 3 (8%) of the 38 patients who received epoetin before surgery and 20 (57%) of the 35 historical controls (P<.001) and that length of hospital stay did not differ significantly between the 2 groups. Our results provide further support for use of epoetin as an effective strategy for reducing exposure to allogenic blood in orthopedic surgery.
Santoro
Jennifer E
JE
Pharmacy Management Department, CalOptima, Orange, California, USA.
Eastlack
Robert K
RK
Mirocha
James M
JM
Bugbee
William D
WD
D000740:Anemia / Q000188:drug therapy*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins; D006801:Humans; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures; D011300:Preoperative Care; D011994:Recombinant Proteins; D012189:Retrospective Studies; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin